CFO of Plus Therapeutics Buys Zero‑Cost RSUs and Options, Betting on Reimbursement Boosts
Plus Therapeutics CFO Andrew MacIntyre buys 349,542 RSUs & options, signaling confidence amid a $0.28 share price, potential reimbursement boost, and volatile outlook.
3 minutes to read